Skip to main navigation Skip to search Skip to main content

Diagnostic Performance of Point-of-Care Immunoassay Measurements of Pancreatic Stone Protein for Sepsis Detection in ICU Patients: A Prospective, Multicenter, Biomarker-Blinded Study

  • Andrew F. Shorr
  • , Marin H. Kollef
  • , Richard G. Wunderink
  • , Luis E. Jauregui-Peredo
  • , Andrew C. Bernard
  • , Hyung Kook Kim
  • , Robert A. Balk
  • , Patricia Cristofaro
  • , Mitchell M. Levy

Research output: Contribution to journalArticlepeer-review

Abstract

Objectives: – To evaluate the diagnostic performance of a rapid point-of-care immunoassay measuring pancreatic stone protein (PSP) for early sepsis identification within the first three days of ICU admission. Subgroup analyses (sex, age, febrile status) were conducted, and the combined diagnostic value of PSP and C-reactive protein (CRP) was assessed. Design: – Multicenter, prospective, observational study. Patient: – Four hundred sixty-six adults the ICU. Setting: – Six ICUs in the United States who were expected to required at least 24 hours of ICU care. Interventions: – None. Measurements and Main Results: – We calculated the Youden Index to evaluate the clinical performance of the PSP assay, and the resulting threshold was used to identify patients with sepsis. Diagnostic performance metrics included sensitivity, specificity, accuracy, positive predictive value (PPV), negative predictive value (NPV), positive likelihood ratio (LR+), and negative likelihood ratio (LR–). Receiver operating characteristic analysis were performed for PSP and CRP. At the optimal PSP cutoff point of 117 ng/mL, PSP demonstrated a sensitivity of 74.2%, specificity of 67.8%, accuracy of 71.0%, PPV of 70.3%, NPV of 71.9%, and LR+ and LR– ratios of 2.30 and 0.38, respectively. Combining PSP and CRP improved diagnostic specificity to 95.2%. Subgroup analyses demonstrated consistent performance across sex, and higher specificity was observed in patients 18–60 years old. In febrile patients, PSP achieved high specificity (87.5%) but lower sensitivity (63.6%). In non-febrile patients, sensitivity and specificity were 67.7% and 76.6%, respectively. Conclusions: – PSP can serve as a biomarker for the early identification of sepsis. Diagnostic performance across diverse ages, sex, and clinical presentation supports the assay’s broad applicability. The combination of PSP and CRP enhances diagnostic specificity for sepsis detection, offering a complementary approach to improve sepsis detection and lead to earlier appropriate management.

Original languageEnglish
JournalCritical Care Medicine
VolumePublish Ahead of Print
DOIs
StatePublished - Mar 4 2026

Bibliographical note

Publisher Copyright:
© 2026

Funding

Dr. Kollef was supported by the Foundation for Barnes-Jewish Hospital. Dr. Schorr received support for article research from Abionic SA (Epalinges, Switzerland). Dr. Balk disclosed off-label use of new assay for pancreatic stone protein. Dr. Cristofaro received funding from Abionic; she received support for article research from Abionic; she disclosed work for hire; she disclosed off-label use of an investigational product. Dr. Levy’s institution received funding from the National Institutes of Health, the National Heart, Lung, and Blood Institute and the AIMS Study. The remaining authors have disclosed that they do not have any potential conflicts of interest.

Funders
Foundation for Barnes-Jewish Hospital
National Institutes of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)

    Keywords

    • biomarker
    • diagnostic
    • pancreatic stone protein
    • point-of-care
    • sepsis

    ASJC Scopus subject areas

    • Critical Care and Intensive Care Medicine

    Fingerprint

    Dive into the research topics of 'Diagnostic Performance of Point-of-Care Immunoassay Measurements of Pancreatic Stone Protein for Sepsis Detection in ICU Patients: A Prospective, Multicenter, Biomarker-Blinded Study'. Together they form a unique fingerprint.

    Cite this